4//SEC Filing
Gilliland Robertson H. 4
Accession 0001213900-18-010083
CIK 0001513525other
Filed
Aug 1, 8:00 PM ET
Accepted
Aug 2, 4:03 PM ET
Size
14.6 KB
Accession
0001213900-18-010083
Insider Transaction Report
Form 4
Gilliland Robertson H.
Director
Transactions
- Purchase
Warrant to purchase common stock
2018-07-31+14,000→ 43,931 total(indirect: By LLC)Exercise: $6.25From: 2018-07-31Exp: 2023-07-31→ Common Stock (43,931 underlying) - Conversion
Common Stock
2018-07-31+29,931→ 95,424 total(indirect: By LLC) - Purchase
Common Stock
2018-07-31+14,000→ 109,424 total(indirect: By LLC) - Conversion
Convertible Note
2018-07-31−29,931→ 0 total(indirect: By LLC)Exercise: $0.44→ Common Stock (29,931 underlying) - Conversion
Warrant to purchase common stock
2018-07-31+29,931→ 29,931 total(indirect: By LLC)Exercise: $6.25From: 2018-07-31Exp: 2023-07-31→ Common Stock (29,931 underlying)
Footnotes (3)
- [F1]The 29,931 shares of common stock and a warrant to purchase 29,931 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $10,000 at a conversion price of $0.44 per share upon consummation of the initial public offering of the issuer on July 31, 2018.
- [F2]Mr. Gilliland is the principal of Keller Enterprises, LLC ("Keller").
- [F3]On July 31, 2018, Keller purchased 14,000 units (the "Units") in the initial public offering of the issuer at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the IPO.
Documents
Issuer
ADIAL PHARMACEUTICALS, INC.
CIK 0001513525
Entity typeother
Related Parties
1- filerCIK 0001718351
Filing Metadata
- Form type
- 4
- Filed
- Aug 1, 8:00 PM ET
- Accepted
- Aug 2, 4:03 PM ET
- Size
- 14.6 KB